Mr. Michael Woudenberg - 14 Nov 2022 Form 4/A - Amendment Insider Report for InMed Pharmaceuticals Inc. (INM)

Role
Chief Operating Officer
Signature
/s/ Eric A. Adams, attorney-in-fact for Mr. Michael Woudenberg
Issuer symbol
INM
Transactions as of
14 Nov 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
18 Nov 2022, 18:33:45 UTC
Date Of Original Report
15 Nov 2022
Previous filing
28 Feb 2022
Next filing
19 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INM Employee Stock Option (Right to Buy) Disposed to Issuer $0 -7,500 -66% $0.000000 3,842 14 Nov 2022 Common shares 7,500 $2.78 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.
F2 On September 7, 2022, the Issuer's common stock was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.
F3 On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 7,500 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,842 derivative securities of the Issuer.